{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:08:02Z","timestamp":1764785282090,"version":"3.40.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jfma.2024.01.031","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T15:45:51Z","timestamp":1706888751000},"page":"788-795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-8908","authenticated-orcid":false,"given":"Po-Ting","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Juei","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Shyan","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2024.01.031_bib1","first-page":"e2","article-title":"Hepatocellular carcinoma","volume":"381","author":"Villanueva","year":"2019","journal-title":"Reply. N Engl J Med"},{"key":"10.1016\/j.jfma.2024.01.031_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jfma.2024.01.031_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12072-016-9774-x","article-title":"HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma","volume":"11","author":"Lin","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2024.01.031_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.01.031_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2024.01.031_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2024.01.031_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2024.01.031_bib8","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2024.01.031_bib9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.01.031_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial","volume":"69","author":"Finn","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2024.01.031_bib11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2024.01.031_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.01.031_bib13","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2024.01.031_bib14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2024.01.031_bib15","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2024.01.031_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2024.01.031_bib17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2024.01.031_bib18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1159\/000510299","article-title":"Lenvatinib-transarterial chemoembolization sequential therapy as an effective treatment at progression during lenvatinib therapy for advanced hepatocellular carcinoma","volume":"9","author":"Kawamura","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jfma.2024.01.031_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010160","article-title":"Alternating lenvatinib and trans-arterial therapy prolongs overall survival in patients with inter-mediate stage HepatoCellular carcinoma: a propensity score matching study","volume":"13","author":"Shimose","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jfma.2024.01.031_bib20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jfma.2020.10.031","article-title":"Diagnosis G, systemic therapy G. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the taiwan liver cancer association and the gastroenterological society of Taiwan","volume":"120","author":"Shao","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2024.01.031_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2024.01.031_bib22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jhep.2011.03.007","article-title":"EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization","volume":"55","author":"Gillmore","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2024.01.031_bib23","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2024.01.031_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000502905","article-title":"A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jfma.2024.01.031_bib25","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.21873\/anticanres.13768","article-title":"Conversion hepatectomy for huge hepatocellular carcinoma with arterioportal shunt after chemoembolization and lenvatinib therapy","volume":"39","author":"Sato","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jfma.2024.01.031_bib26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s40792-020-01078-3","article-title":"Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy","volume":"6","author":"Ohya","year":"2020","journal-title":"Surg Case Rep"},{"key":"10.1016\/j.jfma.2024.01.031_bib27","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.7150\/jca.19964","article-title":"Comparison of combined transcatheter arterial chemoembolization and CT-guided radiofrequency ablation with surgical resection in patients with hepatocellular carcinoma within the up-to-seven criteria: a multicenter case-matched study","volume":"8","author":"Pan","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.jfma.2024.01.031_bib28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1186\/1471-2407-14-849","article-title":"Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma","volume":"14","author":"Yin","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jfma.2024.01.031_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2012.42.9936","article-title":"Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial","volume":"31","author":"Peng","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2024.01.031_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000501281","article-title":"Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma","volume":"97","author":"Hiraoka","year":"2019","journal-title":"Oncology"},{"key":"10.1016\/j.jfma.2024.01.031_bib31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2024.01.031_bib32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000452846","article-title":"Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: a comparison with the liver damage and child-pugh classifications","volume":"6","author":"Hiraoka","year":"2017","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jfma.2024.01.031_bib33","article-title":"Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients","author":"Lin","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2024.01.031_bib34","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/hep.26328","article-title":"Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells","volume":"57","author":"Sprinzl","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2024.01.031_bib35","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/2326-6066.CIR-14-0076","article-title":"Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines","volume":"2","author":"Farsaci","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jfma.2024.01.031_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/0008-5472.CAN-13-1186","article-title":"Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Ralpha and NKG2D triggering","volume":"74","author":"Romero","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jfma.2024.01.031_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.intimp.2017.02.028","article-title":"Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo","volume":"46","author":"Sunay","year":"2017","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.jfma.2024.01.031_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ijc.28362","article-title":"Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity","volume":"134","author":"Chen","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jfma.2024.01.031_bib39","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/labinvest.2010.205","article-title":"Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model","volume":"91","author":"Cao","year":"2011","journal-title":"Lab Invest"},{"key":"10.1016\/j.jfma.2024.01.031_bib40","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00262-012-1380-8","article-title":"Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma","volume":"62","author":"Cabrera","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jfma.2024.01.031_bib41","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/ijc.31216","article-title":"Targeting tumor-infiltrating Ly6G(+) myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma","volume":"142","author":"Chang","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jfma.2024.01.031_bib42","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.21873\/anticanres.13710","article-title":"Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma","volume":"39","author":"Takahashi","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jfma.2024.01.031_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231828","article-title":"Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma","volume":"15","author":"Kirino","year":"2020","journal-title":"PLoS One"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624000846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624000846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:49:26Z","timestamp":1729226966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624000846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0929664624000846"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.01.031","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}